News|Articles|June 24, 2025

ADA 2025 Recap: 7 Trials to Know

This recap highlights data on stem cell-derived therapies for type 1 diabetes, cortisol-modulating strategies for hard-to-treat type 2 diabetes, and a novel once-weekly insulin alternative that matches daily injections in efficacy.

The 2025 American Diabetes Association (ADA) Scientific Sessions held June 20–24 in Chicago spotlighted an expanding vision for diabetes and metabolic care that stretches beyond traditional glucose control. This year’s research emphasized regenerative approaches, hormonal targeting, and alternative insulin delivery—all pushing the field toward more individualized, physiology-informed interventions.

Related to this article

David Kendall, MD | Image Credit: LinkedIn

October 7th, 2026

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

October 4th, 2026

8 Endocrinology Headlines You Missed in Q3 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

W. Timothy Garvey, MD | Image Credit: UAB

October 7th, 2026

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

October 6th, 2026

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

October 6th, 2026

RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.

October 5th, 2026

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.